Please assess the completion status of the following clinical trial:

Trial Title: Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant gestational age \>= 28 weeks~* Systolic blood pressure \>=160 mm Hg OR a diastolic blood pressure of \>=110 mm Hg measured twice more than 15 minutes apart~* Able to swallow pills~* \>= 18 years~Exclusion Criteria:~* Indication for emergent cesarean or known fetal anomaly~* Anti-hypertensive therapy received in the past 12 hours~* History of eclampsia or other adverse CNS complication (e.g., stroke or PRES) in this pregnancy~* Actively wheezing at time of enrollment or history of asthma complications~* Known coronary artery disease or type I DM with microvascular complications or signs of heart failure or clinical dissection of the aorta

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Nifedipine (Type: ACTIVE_COMPARATOR): Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).
- Methyldopa (Type: EXPERIMENTAL): Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
- Labetalol (Type: EXPERIMENTAL): Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).

Based on this trial design, predict the completion outcome and termination type (if applicable).